Plasmodium falciparum malaria

Plasmodium falciparum malaria is a severe form of malaria caused by the protozoan parasite Plasmodium falciparum, characterized by irregularly recurrent paroxysms and prolonged or continuous fever ^[2]. The parasite is transmitted to humans mainly through the bite of infected female Anopheles mosquitoes and can progress rapidly to severe or life-threatening disease, particularly in settings of substantial transmission ^[1].

P. falciparum infection produces a wide clinical spectrum, from absent or very mild symptoms to severe disease and death, with disease typically classified as uncomplicated or severe/complicated ^[1]. Common features include fever, chills, headache, gastrointestinal symptoms, and anemia, while severe presentations may involve neurologic manifestations and organ complications ^[1]. All clinical symptoms arise from the asexual erythrocytic (blood-stage) parasites; when infected erythrocytes lyse, hemozoin pigment and other toxic factors such as glucose phosphate isomerase stimulate macrophages to release cytokines that produce fever and rigors and contribute to severe pathophysiology ^[1].

P. falciparum is common in many endemic settings, with the heaviest burden in sub-Saharan Africa, where substantial exposure contributes to the greatest risk of severe disease ^[1]. The incubation period is typically shorter than that of other Plasmodium species, generally ranging from 7 to 30 days, although antimalarial prophylaxis taken by travelers can delay the appearance of malaria symptoms by weeks or months ^[1].

Most P. falciparum malaria is acquired through the bite of an infective female Anopheles mosquito ^[1]. Rare alternative routes include transfusion of contaminated blood, organ transplantation, needle sharing, and congenital transmission ^[1].

Key prevention strategies for travelers and at-risk populations include avoiding mosquito bites and taking indicated antimalarial prophylaxis as prescribed, which is highly effective when used correctly ^[1]. Whole-sporozoite vaccine platforms—including radiation-attenuated sporozoites, chemoprophylaxis with infectious sporozoites, and genetically attenuated parasites—have demonstrated proof-of-concept for high-grade protection against P. falciparum malaria in humans and are progressing through clinical development ^[3]. Combating the spread of antimalarial resistance, particularly to artemisinin and partner drugs, remains a top priority requiring new antimalarial agents with novel modes of action ^[4].

1. 1US Centers for Disease Control and Prevention. Clinical Features of Malaria | Malaria | CDC [Internet]. cited 3 Sept 2026.Available from: https://www.cdc.gov/malaria/hcp/clinical-features/index.html
2. 2Wikidata contributors. Plasmodium falciparum malaria [Internet]. Wikidata. cited 3 Sept 2026.Available from: https://www.wikidata.org/wiki/Q18554672
3. 3Epstein JE et al. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review. Curr Opin Infect Dis. 2013 Oct. PMID: 23982233. doi: 10.1097/QCO.0000000000000002.PubMed: https://pubmed.ncbi.nlm.nih.gov/23982233/
4. 4Wicht KJ et al. Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annu Rev Microbiol. 2020 Sep 8. PMID: 32905757. doi: 10.1146/annurev-micro-020518-115546.PubMed: https://pubmed.ncbi.nlm.nih.gov/32905757/